VIVIAN OLTI WEISSBRUN: Open Payments
NPI 1417056417 · MIAMI BEACH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,979 in 81 payments from 11 companies in 2025. Trend: 2023 $1,696 · 2024 $1,100 · 2025 $2,979
Food & beverage: $2,913Education: $66
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 21 | $830 |
| E.R. Squibb & Sons, L.L.C. | 6 | $413 |
| Neurocrine BioSciences, Inc. | 13 | $377 |
| Vanda Pharmaceuticals Inc. | 8 | $370 |
| ABBVIE INC. | 13 | $292 |
| Janssen Pharmaceuticals, Inc | 8 | $203 |
| Axsome Therapeutics, Inc. | 4 | $157 |
| Alkermes, Inc. | 4 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $121 |
| Luye Pharma (USA) Ltd. | 2 | $44 |
Products named: UZEDY, COBENFY, INGREZZA, FANAPT, VRAYLAR, AUSTEDO XR, INVEGA SUSTENNA, Auvelity.
Industry payments across FL — which companies pay providers there.
